Cepheid

Cepheid, a highly innovative and profoundly impactful operating company within the Danaher Corporation, is a molecular diagnostics pioneer that has fundamentally revolutionized the accessibility, simplicity, and speed of highly accurate Polymerase Chain Reaction (PCR) testing. Headquartered in Sunnyvale, California, the company’s crowning achievement is the globally ubiquitous GeneXpert® System. This groundbreaking platform successfully transformed complex, highly labor-intensive molecular biology—which traditionally required pristine reference lab environments and highly trained molecular technicians—into a simple, fully automated, closed-cartridge system that can be operated directly at the point of care.

The GeneXpert system seamlessly automates the extraction, amplification, and accurate detection of DNA and RNA from patient samples, typically delivering actionable results in roughly one hour. Utilizing this robust platform, Cepheid provides an incredibly extensive menu of diagnostic assays. Most notably, their Xpert® MTB/RIF test absolutely revolutionized global Tuberculosis diagnosis in strategic partnership with the World Health Organization (WHO). The company also offers highly impactful, rapid diagnostic tests for Healthcare-Associated Infections (HAIs) such as MRSA and C. difficile, sexually transmitted infections, and critical respiratory viruses including COVID-19 and RSV.

By radically decentralizing molecular diagnostics and placing reference-lab-quality PCR testing directly in clinics, emergency rooms, and resource-limited settings globally, Cepheid has drastically reduced the turnaround time for critical diagnostic data. This uncompromising dedication to democratizing diagnostic access enables frontline clinicians to make immediate, highly targeted treatment decisions, fundamentally optimizing patient management and saving countless lives worldwide.